J Gen Virol Faster Access
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Gen Virol 71 (1990), 1275-1282; DOI 10.1099/0022-1317-71-6-1275
© 1990 Society for General Microbiology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Appleyard, G.
Right arrow Articles by Vadolas, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Appleyard, G.
Right arrow Articles by Vadolas, J.
Agricola
Right arrow Articles by Appleyard, G.
Right arrow Articles by Vadolas, J.

Neutralization epitopes of human rhinovirus type 2

G. Appleyard, S. M. Russell, B. E. Clarke, S. A. Speller, M. Trowbridge and J. Vadolas

Department of Virology, Wellcome Biotechnology Ltd, Langley Court, Beckenham, Kent BR3 3BS, U.K.

Fourteen neutralizing monoclonal antibodies recognizing human rhinovirus (HRV) type 2 have been used to select a total of 51 virus escape mutants. Cross-resistance analysis of the mutants, together with RNA sequencing and identification of amino acid substitutions, have revealed three neutralization sites on the virus surface. Two of these appear to correspond to the NIm-IA and NIm-II sites described for HRV-type 14, although there are also substantial differences. The third site has not been described previously.

Received 15 November 1989; accepted 26 January 1990.


This article has been cited by other articles:


Home page
 J. Virol.Home page
M. Dan and J. K. Chantler
A Genetically Engineered Attenuated Coxsackievirus B3 Strain Protects Mice against Lethal Infection
J. Virol., July 15, 2005; 79(14): 9285 - 9295.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
F. Li, R. A. Stevenson, B. S. Crabb, M. J. Studdert, and C. A. Hartley
Several Recombinant Capsid Proteins of Equine Rhinitis A Virus Show Potential as Diagnostic Antigens
Clin. Vaccine Immunol., June 1, 2005; 12(6): 778 - 785.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
E. Stadnick, M. Dan, A. Sadeghi, and J. K. Chantler
Attenuating Mutations in Coxsackievirus B3 Map to a Conformational Epitope That Comprises the Puff Region of VP2 and the Knob of VP3
J. Virol., December 15, 2004; 78(24): 13987 - 14002.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
P. Joki-Korpela, M. Roivainen, H. Lankinen, T. Pöyry, and T. Hyypiä
Antigenic properties of human parechovirus 1
J. Gen. Virol., July 1, 2000; 81(7): 1709 - 1718.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
E. A. Hewat, T. C. Marlovits, and D. Blaas
Structure of a Neutralizing Antibody Bound Monovalently to Human Rhinovirus 2
J. Virol., May 1, 1998; 72(5): 4396 - 4402.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 1990 by the Society for General Microbiology.